

Resource Summary Report

Generated by [NIF](#) on Aug 31, 2026

KG-1

RRID:CVCL_0374

Type: Cell Line

Proper Citation

RRID:CVCL_0374

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0374

Proper Citation: RRID:CVCL_0374

Description: Cell line KG-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Acute myeloid leukemia without maturation

Defining Citation: [PMID:306682](#), [PMID:1571549](#), [PMID:2140233](#), [PMID:2985879](#), [PMID:3094604](#), [PMID:3159941](#), [PMID:3856862](#), [PMID:3874327](#), [PMID:6582512](#), [PMID:6954533](#), [PMID:6996765](#), [PMID:8558913](#), [PMID:9290701](#), [PMID:9379676](#), [PMID:9510473](#), [PMID:10739008](#), [PMID:11021758](#), [PMID:11226526](#), [PMID:14504097](#), [PMID:15843827](#), [PMID:16408098](#), [PMID:17254797](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:22844360](#), [PMID:23955599](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:31395879](#), [PMID:35839778](#), [PMID:36982453](#)

Comments: Characteristics: Mostly at the myeloblast or promyelocyte stage of maturation., Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: FGFR genetic alteration cell panel (ATCC TCP-1034)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: KG-1

Synonyms: KG1

Cross References: BTO:BTO_0000670, CLO:CLO_0007093, CLO:CLO_0007094, CLO:CLO_0051560, EFO:EFO_0002218, MCCL:MCC:0000269, CLDB:cl3022, CLDB:cl3023, CLDB:cl3024, CLDB:cl3025, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, ATCC:CCL-246, ATCC:CRL-8031, BCRC:60158, BCRJ:0132, BioSample:SAMN01821643, BioSample:SAMN03473103, BioSample:SAMN10988135, cancercellines:CVCL_0374, CCRID:4201HUM-CCTCC00121, CCTCC:GDC0121, Cell_Model_Passport:SIDM00785, ChEMBL-Cells:ChEMBL3307794, ChEMBL-Targets:ChEMBL612264, CLS:300208, Cosmic:683545, Cosmic:717682, Cosmic:787443, Cosmic:850386, Cosmic:851998, Cosmic:907278, Cosmic:919118, Cosmic:924047, Cosmic:947365, Cosmic:975261, Cosmic:981581, Cosmic:985581, Cosmic:996311, Cosmic:998743, Cosmic:999726, Cosmic:1012078, Cosmic:1019831, Cosmic:1037660, Cosmic:1070689, Cosmic:1078730, Cosmic:1107180, Cosmic:1127253, Cosmic:1150903, Cosmic:1176582, Cosmic:1181606, Cosmic:1197928, Cosmic:1281321, Cosmic:1308223, Cosmic:1523823, Cosmic:1524832, Cosmic:1582389, Cosmic:1623637, Cosmic:2060796, Cosmic:2089672, Cosmic:2131541, Cosmic:2306212, Cosmic:2750861, Cosmic-CLP:907278, DepMap:ACH-000386, DSMZ:ACC-14, DSMZCellDive:ACC-14, ECACC:86111306, EGA:EGAS00001000610, EGA:EGAS00001000978, FANTOM5_SSTAR:10827-111C8, GDSC:907278, GEO:GSM236787, GEO:GSM236823, GEO:GSM887208, GEO:GSM888281, GEO:GSM1374597, GEO:GSM1446744, GEO:GSM1669984, IARC_TP53:2195, IGRhCellID:KG1, IZSLER:BS TCL 190, JCRB:JCRB0065, JCRB:JCRB9051, KCB:KCB 200552YJ, KCLB:10246, LiGeA:CCLE_811, LINCS_LDP:LCL-1056, Lonza:746, NCBI_Iran:C119, PharmacDB:KG1_744_2019, PRIDE:PXD030304, Progenetix:CVCL_0374, PubChem_Cell_line:CVCL_0374, RCB:RCB1166, RCB:RCB1944, TKG:TKG 0400, Wikidata:Q54899833

ID: CVCL_0374

Record Creation Time: 20220427T220702+0000

Record Last Update: 20260829T234411+0000

Ratings and Alerts

No rating or validation information has been found for KG-1.

Warning: Discontinued: TKG; TKG 0400

Characteristics: Mostly at the myeloblast or promyelocyte stage of maturation., Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: FGFR genetic alteration cell panel (ATCC TCP-1034)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Warning: Discontinued: RCB; RCB1944

Characteristics: Mostly at the myeloblast or promyelocyte stage of maturation., Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: FGFR genetic alteration cell panel (ATCC TCP-1034)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 228 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Peng M, et al. (2026) MMRN1-EGFR drives sialylglycan-Siglec immune evasion in AML leukemia stem cells. *Cell stem cell*, 33(5), 800.

Resch V, et al. (2026) Targeting Steroid-Metabolizing Enzymes with 15 β -Substituted Estrone Analogues: Dual Discovery of AKR1C2/17 β -HSD1 Inhibitors and a Fluorescent 17 β -HSD1 Ligand. *Cancers*, 18(12).

Kořánová T, et al. (2026) PD-L1 Expression in Acute Myeloid Leukemia Cells: Associations With Cell Metabolism. *Journal of immunology research*, 2026(1), e1427790.

Wang Y, et al. (2026) Tuning the sensitivity of mechanosensory receptors through histidine scanning. *Cell*, 189(6), 1680.

Peng J, et al. (2026) m6A Modification of ATOX1 Inhibits Acute Myeloid Leukemia Progression by Promoting Cuproptosis. *Cancer research communications*, 6(4), 714.

Waclawiczek A, et al. (2026) Leukemic stem cell subtypes determine venetoclax resistance and therapeutic vulnerabilities in AML. *Cell stem cell*, 33(6), 982.

Pereira-Martins DA, et al. (2026) β Np73 isoform defines a TP53-mutant-like poor-risk subgroup of acute myeloid leukemia. *Cell reports. Medicine*, 102540.

Leesang TE, et al. (2025) Retinoic acid and ascorbate synergize to suppress myeloid leukemia via TET2 activation. *Cell reports*, 44(10), 116379.

Yuan Y, et al. (2025) CircTADA2A inhibits cell proliferation and promotes ferroptosis by sponging miR-638 in acute myeloid leukemia. *Human cell*, 38(5), 123.

Porazzi P, et al. (2025) EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models. *Cancer cell*, 43(3), 537.

Guillen Magaña JN, et al. (2025) Schlafen 12 Modulation and Targeting in Acute Myeloid Leukemia. *Cancer research communications*, 5(11), 2012.

Shang K, et al. (2025) CD97-directed CAR-T cells with enhanced persistence eradicate acute myeloid leukemia in diverse xenograft models. *Cell reports. Medicine*, 6(6), 102148.

Wang Z, et al. (2025) Energy Deficiency-Induced ATG4B Nuclear Translocation Inhibits PRMT1-Mediated DNA Repair and Promotes Leukemia Progression. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), e09838.

Yanagiya R, et al. (2025) Aberrant expression of human endogenous retrovirus K9-derived elements is associated with better clinical outcome of acute myelocytic leukemia. *Retrovirology*, 22(1), 4.

Schmitt N, et al. (2025) The bispecific innate cell engager AFM28 eliminates CD123+ leukemic stem and progenitor cells in AML and MDS. *Nature communications*, 16(1), 7793.

Li S, et al. (2025) The m5C methyltransferase NSUN2 promotes progression of acute myeloid leukemia by regulating serine metabolism. *Cell reports*, 44(5), 115661.

Shen Y, et al. (2024) Coptisine exerts anti-tumour effects in triple-negative breast cancer by targeting mitochondrial complex I. *British journal of pharmacology*, 181(21), 4262.

Xia L, et al. (2024) Osimertinib Covalently Binds to CD34 and Eliminates Myeloid Leukemia Stem/Progenitor Cells. *Cancer research*, 84(3), 479.

Diepstraten ST, et al. (2024) Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers. *Cancer cell*, 42(5), 850.

Lee S, et al. (2024) B7H6 is the predominant activating ligand driving natural killer cell-mediated killing in patients with liquid tumours: evidence from clinical, in silico, in vitro, and in vivo studies. *EBioMedicine*, 110, 105459.